E-ISSN 2534-9821
 

Case Report 


Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer

Wenhan Cheng, Eldon Brown, Matt Gorman, Timothy Babushok.

Abstract
Immune checkpoint blockade therapy (ICB) targets immune suppressive checkpoint proteins, such as programmed cell death 1 (PD-1) / programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA 4) pathways. It exhibits a significant advantage in non-small cell lung cancer (NSCLC) treatment. Number of Patients with immune related adverse events (irAEs) are likely to grow due to the large amounts of patients being administered ICB for NSCLC. This report demonstrates a case of aplastic anemia (AA) secondary to ICB therapy in a patient with NSCLC, and a specific treatment for the AA by immune suppression therapy (IS). The study of IS therapy indicates it is an important therapeutic tool for patients with AA; however, it is unclear how IS therapy works for NSCLC patients with a secondary AA under an ICB treatment. This clinical case provides a positive result and indicates IS therapy can be used on AA secondary to ICB therapy. More study is needed to investigate for potential side effects of this treatment.

Key words: Immune checkpoint blockade therapy (ICB), Non-small cell lung cancer (NSCLC), Immune suppression therapy (IS), Aplastic anemia (AA), Atezolizumab, Anti-lymphocyte globulin (ALG)


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Wenhan Cheng
Articles by Eldon Brown
Articles by Matt Gorman
Articles by Timothy Babushok
on Google
on Google Scholar
Article Statistics
 Viewed: 627
Downloaded: 52


How to Cite this Article
Pubmed Style

Cheng W, Brown E, Gorman M, Babushok T. Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer. Int J Med Rev Case Rep. 2020; 4(1): 18-21. doi:10.5455/IJMRCR.atezolizumab-non-small-cell-lung-cancer


Web Style

Cheng W, Brown E, Gorman M, Babushok T. Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer. http://www.mdpub.net/?mno=72395 [Access: April 03, 2020]. doi:10.5455/IJMRCR.atezolizumab-non-small-cell-lung-cancer


AMA (American Medical Association) Style

Cheng W, Brown E, Gorman M, Babushok T. Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer. Int J Med Rev Case Rep. 2020; 4(1): 18-21. doi:10.5455/IJMRCR.atezolizumab-non-small-cell-lung-cancer



Vancouver/ICMJE Style

Cheng W, Brown E, Gorman M, Babushok T. Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer. Int J Med Rev Case Rep. (2020), [cited April 03, 2020]; 4(1): 18-21. doi:10.5455/IJMRCR.atezolizumab-non-small-cell-lung-cancer



Harvard Style

Cheng, W., Brown, . E., Gorman, . M. & Babushok, . T. (2020) Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer. Int J Med Rev Case Rep, 4 (1), 18-21. doi:10.5455/IJMRCR.atezolizumab-non-small-cell-lung-cancer



Turabian Style

Cheng, Wenhan, Eldon Brown, Matt Gorman, and Timothy Babushok. 2020. Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer. International Journal of Medical Reviews and Case Reports, 4 (1), 18-21. doi:10.5455/IJMRCR.atezolizumab-non-small-cell-lung-cancer



Chicago Style

Cheng, Wenhan, Eldon Brown, Matt Gorman, and Timothy Babushok. "Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer." International Journal of Medical Reviews and Case Reports 4 (2020), 18-21. doi:10.5455/IJMRCR.atezolizumab-non-small-cell-lung-cancer



MLA (The Modern Language Association) Style

Cheng, Wenhan, Eldon Brown, Matt Gorman, and Timothy Babushok. "Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer." International Journal of Medical Reviews and Case Reports 4.1 (2020), 18-21. Print. doi:10.5455/IJMRCR.atezolizumab-non-small-cell-lung-cancer



APA (American Psychological Association) Style

Cheng, W., Brown, . E., Gorman, . M. & Babushok, . T. (2020) Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer. International Journal of Medical Reviews and Case Reports, 4 (1), 18-21. doi:10.5455/IJMRCR.atezolizumab-non-small-cell-lung-cancer